Menopause & midlife

Bleeding on HRT: Expected Early, Checked If Late

Save

Spotting in the first 3 to 6 months of continuous hormone therapy is expected as the lining adjusts. Bleeding that lasts beyond about 6 months, or returns after months of none, is worth checking — usually benign, but evaluation rules out endometrial causes. A transvaginal ultrasound or biopsy may be part of that assessment.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Is spotting on HRT normal at first?

Unscheduled spotting is one of the most common early effects of continuous hormone therapy, reported by many people in the first months 2. The uterine lining takes time to adjust to steady estrogen and progestogen, and light, irregular bleeding during that settling period is expected rather than alarming 1. According to the North American Menopause Society, bleeding patterns depend heavily on the regimen: continuous combined therapy often causes early spotting that fades, while sequential therapy is designed to produce a scheduled monthly bleed 2. In perimenopause, irregular bleeding is expected anyway as cycles wind down, so spotting is read differently than in someone years past her final period 1. Tracking when bleeding happens, alongside other menopause symptoms, helps a clinician interpret it.

When does bleeding on HRT need checking?

Bleeding earns a closer look once it falls outside the expected early window. Guidelines generally treat unscheduled bleeding that persists beyond about 6 months of continuous therapy — or that begins after a stretch of no bleeding — as a reason to be assessed 1. According to NICE, the timing and pattern of bleeding guide whether and how quickly to investigate 1. The concern is not that bleeding usually signals cancer; most cases have a benign cause such as lining adjustment, a missed dose, or absorption changes 2. Because unscheduled bleeding can occasionally be the first sign of endometrial hyperplasia or cancer, checking is how clinicians rule that out early 3.

What does an evaluation for bleeding involve?

An evaluation for unscheduled bleeding is usually quick and focused. A clinician typically starts with your history and a pelvic examination, then may arrange a transvaginal ultrasound to measure the thickness of the uterine lining 3. If the lining is thickened or the picture is unclear, an endometrial biopsy — a small sample taken in the office — can check the cells directly 3. According to the National Cancer Institute, abnormal or postmenopausal bleeding is the most common symptom that prompts evaluation for endometrial cancer, which is why it is not ignored 3. Reviewing the regimen itself, including dose and how consistently it is used, is often part of the same visit 2.

How does your HRT regimen affect bleeding?

The bleeding you can expect depends on which regimen you use. Sequential (cyclical) therapy, often chosen in perimenopause, deliberately produces a predictable monthly withdrawal bleed 1. Continuous combined therapy, more common after menopause, aims for no bleeding at all once the lining settles, usually within 3 to 6 months 1. Switching between regimens, changing the progestogen, or missing doses can each restart spotting 2. The North American Menopause Society notes that the progestogen component is what protects the lining, so a change in bleeding is sometimes a signal to review that part of the plan 1. A hormone therapy review can match the regimen to your stage and goals.

When bleeding on HRT needs a gynecologist

A clinician can distinguish expected settling from bleeding that deserves a workup. Someone tracking new or persistent bleeding — especially after months of none — benefits from an assessment that checks the lining and reviews the regimen together 1. A gynecologist or menopause-experienced clinician can order the right test and adjust therapy if bleeding reflects the dose or progestogen rather than anything worrying 3. Understanding how irregular perimenopausal bleeding and the wider perimenopausal transition shape what is normal can make that visit more useful. Gale can help you prepare for that conversation.

Common questions

Yes. Light, irregular spotting is common in the first 3 to 6 months of continuous hormone therapy while the uterine lining adjusts to steady estrogen and progestogen. It usually settles on its own and does not, by itself, signal a problem.

Bleeding that continues beyond about 6 months of continuous therapy, or that starts again after a bleed-free stretch, is the pattern most guidelines suggest evaluating. The goal is to rule out other causes early, since most such bleeding turns out to be benign.

A clinician usually starts with your history and a pelvic exam, then may arrange a transvaginal ultrasound to measure the lining thickness. If needed, an endometrial biopsy taken in the office checks the cells. The regimen and adherence are often reviewed at the same visit.

Yes. Sequential therapy is designed to give a scheduled monthly bleed, while continuous combined therapy aims for no bleeding once the lining settles. Switching regimens, changing the progestogen, or missing doses can restart spotting, so the expected pattern depends on your plan.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When bleeding on HRT needs assessment

  • Unscheduled bleeding that lasts beyond about 6 months of continuous therapy, or begins after months of none, is a reason to arrange evaluation.
  • Any bleeding after a clear postmenopausal, bleed-free stretch is a reason to seek clinician review.
  • Heavy bleeding that soaks through protection, or bleeding with dizziness or feeling faint, is a reason to seek urgent medical care.
  • New pelvic pain, or bleeding with a change in vaginal discharge, is a reason to contact your clinician.

This article is general health education, not medical advice. Whether bleeding on hormone therapy needs testing or a change in regimen is a decision to make with a gynecologist or a menopause-experienced clinician.

References

  1. 1.National Institute for Health and Care Excellence (2026). Menopause: identification and management (NG23). National Institute for Health and Care Excellence (NICE). linkGuidance that unscheduled bleeding persisting beyond the early months of HRT, or starting after a bleed-free period, warrants assessment, and that bleeding patterns depend on the regimen.
  2. 2.The North American Menopause Society (Menopause Society) (2022). The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. doi:10.1097/GME.0000000000002028Bleeding patterns on continuous versus sequential regimens, the endometrial-protective role of the progestogen, and benign causes of breakthrough bleeding.
  3. 3.National Cancer Institute (PDQ Adult Treatment Editorial Board) (2020). Endometrial Cancer Treatment (PDQ®)–Patient Version. National Cancer Institute (NCI), NIH. linkAbnormal or postmenopausal bleeding as the most common symptom prompting evaluation for endometrial hyperplasia and cancer, assessed by transvaginal ultrasound and endometrial biopsy.

3 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy